Phenylketonuria Market Analysis Overview Report - 2030

Phenylketonuria (PKU) is a rare genetic disorder that affects the body's ability to process phenylalanine, an amino acid found in most proteins. If untreated, PKU can lead to intellectual disability, seizures, behavioral problems, and other serious health issues. The PKU market primarily comprises dietary supplements, newborn screening tests, and therapeutic treatments.

Phenylketonuria Market Drivers

Increasing prevalence of PKU: The global prevalence of PKU is on the rise due to improved newborn screening programs and increased awareness. This has led to a growing demand for PKU products and services.

Advancements in treatment and management: The development of low-protein formulas and dietary supplements has significantly improved the quality of life for individuals with PKU. Additionally, advancements in genetic testing and newborn screening have enabled earlier diagnosis and intervention.

Rising healthcare expenditure: Increased healthcare spending, particularly in developed countries, has fueled the growth of the PKU market. Governments and private insurers are investing more in the diagnosis, treatment, and management of rare genetic disorders like PKU.

Phenylketonuria Market Key Players

The PKU market is dominated by a few key players, including:

• Cambrooke Therapeutics
• American Gene Technologies International, Inc.
• Castle Crek Biosciences, Inc.
• Synlogic
• Pristine Organics
• Galen Pharma
• BioMarin Pharmaceutical, Inc.
• PTC Therapeutics
• Relief Therapeutics Holding SA
• Codexis, Inc.
• Agios Pharmaceuticals Inc

Phenylketonuria Market Segmentation